Metolazone
Diulo, Mykrox, Zaroxolyn (metolazone) is a small molecule pharmaceutical. Metolazone was first approved as Diulo on 1982-01-01. It is used to treat edema, heart failure, hypertension, and nephrotic syndrome in the USA. The pharmaceutical is active against solute carrier family 12 member 3.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
urogenital diseases | D000091642 |
cardiovascular diseases | D002318 |
signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
metolazone | ANDA | 2023-04-12 |
mykrox tablets | 2006-01-12 | |
zaroxolyn | New Drug Application | 2016-08-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
edema | — | D004487 | R60.9 |
heart failure | EFO_0003144 | D006333 | I50 |
hypertension | EFO_0000537 | D006973 | I10 |
nephrotic syndrome | EFO_0004255 | D009404 | N04 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03B: Low-ceiling diuretics, excl. thiazides
— C03BA: Sulfonamides, low-ceiling diuretics, plain
— C03BA08: Metolazone
— C03E: Diuretics and potassium-sparing agents in combination
— C03EA: Low-ceiling diuretics and potassium-sparing agents
— C03EA12: Metolazone and potassium-sparing agents
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | METOLAZONE |
INN | metolazone |
Description | Metolazone is a quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics. It has a role as a diuretic, an antihypertensive agent and an ion transport inhibitor. It is a member of quinazolines, an organochlorine compound and a sulfonamide. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C |
Identifiers
PDB | — |
CAS-ID | 17560-51-9 |
RxCUI | — |
ChEMBL ID | CHEMBL878 |
ChEBI ID | 64354 |
PubChem CID | 4170 |
DrugBank | DB00524 |
UNII ID | TZ7V40X7VX (ChemIDplus, GSRS) |
Target
Agency Approved
SLC12A3
SLC12A3
Organism
Homo sapiens
Gene name
SLC12A3
Gene synonyms
NCC, TSC
NCBI Gene ID
Protein name
solute carrier family 12 member 3
Protein synonyms
Na-Cl cotransporter, Na-Cl symporter, NaCl electroneutral thiazide-sensitive cotransporter, NCC, sodium-chloride co-transporter, solute carrier family 12 (sodium/chloride transporter), member 3, thiazide-sensitive Na-Cl cotransporter, Thiazide-sensitive sodium-chloride cotransporter
Uniprot ID
Mouse ortholog
Slc12a3 (20497)
solute carrier family 12 member 3 (P59158)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,044 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more